The chief executive officer of Health Catalyst sold $37,348 worth of stock Via Investing.com

Linda Llewelyn, Chief People Officer at Health Center Inc. (NASDAQ:), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On January 15, Llewelyn sold 6,442 shares of common stock at an average price of $5.7976 per share, for a total of $37,348. Following this transaction, Llewelyn still owns 92,260 shares of the company’s stock. The sale was made under a proposed business plan established in March 2024, pursuant to Rule 10b5-1. The sale comes as Health Catalyst is trading near its 52-week low of $5.35, and the stock is down more than 20% in the past. a week. To follow InvestingPro review, the stock appears to be undervalued at current levels, and analysts are projecting a profit this year despite recent market pressure. InvestingPro subscribers have access to 8 key insights about Health Catalyst, including detailed financial health information and comprehensive quality metrics.

In other recent news, Health Catalyst has been the focus of several important events. The company has announced a definitive agreement to acquire Upfront Health Services (NASDAQ:), a provider of patient engagement platforms, which is expected to close in the first quarter of 2025. The acquisition aims to enhance the existing portfolio of Health Catalyst patients and better manage patient care.

Health Catalyst also revealed its strong third-quarter financial results for 2024, with revenue mixed back to software. Analyst firms such as KeyBanc Capital Markets, Piper Sandler, and Stephens expressed optimism for the company’s performance, improving the stock and raising the price target. KeyBanc upgraded Health Catalyst from Sector Weight to Overweight, while Piper Sandler and Stephens increased the company’s stock price target.

In relation to analysts’ ratings, RBC Capital reduced the stock target for Health Catalyst to $7, maintaining a Sector Perform rating. This decision reflects the firm’s cautious stance as they monitor Health Catalyst’s ability to translate new customer bookings into sustainable revenue growth. However, the firm expressed optimism about Health Catalyst’s supply forecast for 2025, expecting around 40 new customers.

These are the latest updates that provide investors with insight into Health Catalyst’s financial health and growth potential. The company’s actions and financial results, as well as the opinions of various analyst firms, provide a picture of the current state of the business of Health Catalyst.

This article was created with the support of AI and reviewed by the editor. For more details, see our T&C.